Global Liver Disease Treatment Market Projections, SWOT Analysis, Risk Analysis, Trends and Forecast by 2021

The Global Liver Disease Treatment Market is expected to reach USD 17.25 billion by 2021 from USD 9.25 billion in 2016, growing at a CAGR of 11.72% during the forecast period, 2016-2021. Liver is a vital organ of the body performing umpteen complex functions such as fighting infections, removing toxins, bile secretion, and it produces clotting factors, proteins, and cholesterol, among others. Malfunctioning of liver can be life-threatening as it can cause multiple acute and chronic diseases (hepatitis, non-alcoholic fatty liver disease, liver cancer, liver tumour, and liver cirrhosis, among others). The initial symptoms of liver damage include nausea, fatigue, diarrhoea, jaundice, swollen abdomen, and mental disorientation among other. Acute liver damage can be treated through proper medication, if detected early, otherwise liver transplant is required. Liver damage can be prevented by adopting healthy lifestyle and practicing proper hygiene.

Browse the report: http://www.orbisresearch.com/reports/index/liver-disease-treatment-market-by-treatment-modality-by-disease-type-and-by-region-global-industry-analysis-size-share-growth-trends-and-forecasts-2016-2021

The growth of Liver Disease Treatment market is majorly driven by factors such as boost in Research & Development investment, unorganized lifestyle, rising public awareness, growth in geriatric population, and unmet needs for the treatment of liver cancer. Additionally, spur in demand for alcohol has increased the risk of liver cirrhosis. According to World Health Organization, alcohol consumption is anticipated to cause 20% to 50% of cirrhosis of the liver. Also, growing obese population has also increased the risk of non-alcoholic fatty liver disease which is caused by build-up of fat in the liver. The obese population has doubled since 1980. In 2014, approximately 13% of the world’s population, that is, more than 600 million adults were obese as per World Health Organization. The key restraints of the market are complex drug approval procedure, side-effects of the product (fatigue, fever, and depression), high cost incurred for product’s R&D process, and competition from alternative medicine (Herbal, Natural medicine).

The global Liver Disease Treatment Market is segmented on the basis of Treatment Modality and Disease Type. Based on Treatment Modality, the market is classified into Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents, Corticosteroids, and Others. On the basis of Disease Type, the market is classified into Hepatitis, Non-Alcoholic Fatty Liver Disease, Alcohol Induced, Liver Cancer, and Others.

Request a sample of the report: http://www.orbisresearch.com/contacts/request-sample/331458

The market has also been geographically segmented into North America, Europe, Asia-Pacific and the Middle-East and Africa. North America is expected to command the major market share of 39% in 2016 followed by Europe. Asia Pacific is anticipated to be the fastest growing region for the product with a CAGR of 12.51% during the forecast period 2016-2021.

The major companies dominating the global Liver Disease Treatment Market are Gilead Science Inc. (U.S.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Johnson & Johnson (U.S.), Novartis (Switzerland), Roche (Switzerland), Sanofi-Aventis (France), Abbott Laboratories (U.S.), Bayer Schering AG (Germany), and AstraZeneca (United Kingdom).

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Information:

Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Email: sales@orbisresearch.com

This release was published on openPR.